Stanford scientists designed a nanobody platform to inhibit the activity of granulysin, a protein that is often found in arterial plaque and released by T cells, to prevent the development of atherosclerosis such as heart attack and strokes.
The Stanford Sarafan ChEM-H Medicinal Chemistry Knowledge Center has developed a novel aqueous solubilizing promoiety (Sol-moiety) that can be readily attached to a wide-range of functional groups and undergo controlled cleavage to improve the pharmacokinetic profile of a desi